Redx Pharma Plc

ACTIVE

United Kingdomwww.redxpharma.comPublic51–100 employeesEstablished: 2010-01-01

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2010

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

66.7%

Phase 2

33.3%

Trial Status Distribution

Active, not recruiting

44.4%

Completed

44.4%

Recruiting

11.1%

Clinical Trials

Trials sponsored by this organization (9)

A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with IPF.

Phase 1

Recruiting

interventional

Dec 202264 participants

A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with IPF.

Phase 1

Active, not recruiting

interventional

Dec 202264 participants

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Phase 2

Active, not recruiting

interventional

Sep 202248 participants

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Phase 2

Completed

interventional

Dec 202145 participants

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Phase 2

Completed

interventional

Nov 202125 participants

Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination with Nivolumab, in Patients with Metastatic, Colorectal Cancer who have Progressed following Therapy with Current Standard of Care

Phase 1

Active, not recruiting

Jul 202160 participants

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Phase 1

Completed

interventional

May 202190 participants

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Phase 1

Completed

interventional

Mar 201946 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations